Figure legends
- Patient enrollment. Based on this, a total of 969 COVID-19 patients
were evaluated for eligibility. Of those, 194 participants were
included in the study and were divided into two groups, favipiravir
(n=101) and HQ (n=93). HQ, hydroxychloroquine; ECG,electrocardiography.
- Comparison of post-treatment data of the two groups. The
post-treatment proportion of arrhythmic events (Panel A )
(13.9% vs. 19.8%) and sinus bradycardia (Panel B ) (3.2%
vs. 13.9%) between the groups. The comparison of ΔHR (Panel
C ) (12 [IQR:-6—70] vs. 5 [IQR:-8—41]) and ΔQTc
(Panel D ) (11 [IQR:-9—57] vs. 12 [IQR:-7—103])
between the groups. HR, heart rate; HQ,hydroxychloroquine; QTc, corrected QT; ΔHR, the
initial and final heart rate difference; ΔQTc, the final and
initial QTc interval difference.
- HR (Panel A, Panel B ) and QTc interval (Panel C,
Panel D ) changes in patients pre/post-treatment. HR, heart
rate; HQ, hydroxychloroquine; QTc, corrected QT.